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Background: Clinically silent cerebral ischemia (SCI) detected by diffusion-weighted MRI has been reported in
5–40% of patients undergoing pulmonary vein isolation (PVI). Although initial reports suggested a high rate of
SCI with phased radiofrequency (RF) ablation on use of the pulmonary vein ablation catheter (PVAC), the
incidence was subsequently markedly reduced in consequence of procedural modiﬁcations in recent studies.
We analyzed cerebral microembolization as assessed with transcranial Doppler during phased RF ablation and
with two other single-shot AF ablation technologies: the cryoballoon (CB) and the nMARQ™multipolar irrigated
RF ablation system.
Methods and results: A total of 89 patients (mean age: 57, SD: 12 years; 62males) with paroxysmal or persistent
AF underwent PVI. Phased RF was used according to the initial protocol in 7 patients (PVAC Group I), with
procedural modiﬁcations and a newer (14.4) version of the RF generator in 37 patients (PVAC Group II) and
with the most recent (version 15.1) generator in 18 patients (PVAC Group III). Ablation was performed with
the CB in 13 and with the nMARQ system in 14 patients.
The number of microemboli (mean + (SD)) detected in the middle cerebral arteries was 2703 (918) in PVAC
Group I, 1087 (542) in PVAC Group II, 719 (469) in PVAC Group III, 1057 (784) with CB and 2166 (1047) with
nMARQ (p b 0.01).
Conclusion: Signiﬁcant decreases inMES countswere observed thanks to the proceduralmodiﬁcations and newer
RF generator with phased RF. HighMES counts comparable to those with the initial phased RF resulted from the
use of nMARQ.© 2014 Published by Elsevier Ireland Ltd.1. Introduction
Pulmonary vein (PV) isolation (PVI) is an establishedmethod for the
treatment of atrial ﬁbrillation (AF), with a relatively low risk (b1%) of
major periprocedural complications, including clinical stroke or
transient ischemic attack (TIA) [1]. However, signiﬁcant concern has
been raised regarding the long-term safety of PVI as clinically silent
cerebral ischemia (SCI) detected by diffusion-weighted (DW) MRI has
been reported in 5–40% of the patients, depending on the ablation
technology used [2–8]. Further, the limited data available suggest that
a cognitive decline potentially related to SCI can be demonstrated sever-
al months after these ablations in some patients. In some studies, a
markedly higher incidence of SCI was reported after PVI performed
with phased radiofrequency (RF) and the PV ablation catheter (PVAC),
as compared with the cryoballoon (CB) or focal irrigated RF ablationersity of Debrecen, 22Móricz Zs.
x: +36 52414928.
ability and freedom frombias of[2,3]. More recent reports with phased RF ablation, however, demon-
strated a signiﬁcant decrease in the incidence of SCI, these favorable
results were attributed to the use of more rigorous periprocedural
anticoagulation protocols and some speciﬁc modiﬁcations in the
procedural technique [9–11]. These procedural changes were based on
the results of animal studies [12,13] and included the avoidance of over-
lap between 2 electrodes during RF applications and careful sheath
management to prevent air embolization. Software modiﬁcations
reﬁning the power handling of the GENius RF generator have also
been implemented.
The recording ofmicroembolic signals (MESs) in themiddle cerebral
arteries (MCAs) by transcranial Doppler (TCD) has been used to assess
microembolization during different cardiovascular procedures [14–16].
Although DWMRI is regarded as the gold standard for the demonstra-
tion of cerebral lesions post-ablation, recording of the MESs provides
a unique opportunity through which to monitor the intensity of
microembolus generation during different phases of the procedure. In
line with the initial DWMRI results, when we used the earlier version
of the GENius generator we detected a signiﬁcantly higher number of
MESs during ablation with the PVAC as compared with the CB [17].
Further, we demonstrated that the majority of the microemboli were
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while the rate of microembolization was relatively uniform throughout
the procedure with the CB. Whether the procedural and technical
modiﬁcations which decreased lesion formation on DW MRI with
the phased RF technology would also reduce the microembolization
detected by TCD is unknown.
Phased RF ablations with the PVAC have been performed for 5 years
in our center, using subsequent versions of the GENius RF generator
together with speciﬁc procedural modiﬁcations to improve safety as
suggested by the literature data. MESs are detected with TCD routinely
during all AF procedures in our laboratory. In this study, we analyzed
our TCD data obtained with phased RF ablations in relation to the
procedural changes implemented in recent years. In order to view
these results in context with other single-shot AF ablation technologies
designed for fast and simpliﬁed PVI, we have compared the MES data
with those obtained by using the CB and the novel nMARQ™ (Biosense
Webster, Inc., Diamond Bar, CA, USA) multipolar irrigated RF ablation
system.
2. Methods
2.1. Patients
Consecutive patients undergoing PVI for symptomatic paroxysmal or persistent AF
not adequately controlled by at least one antiarrhythmic drug were considered for inclu-
sion in the study. Exclusion criteria included long-standing persistent AF, hyper- and
hypothyroidism, signiﬁcant valvular heart disease, heart failure of NYHA class III or IV, a
left ventricular (LV) ejection fraction ≤40%, a left atrial (LA) diameter exceeding 50 mm,
a LA thrombus, unstable angina or myocardial infarction within the last 3 months, severe
chronic obstructive pulmonary disease, known bleeding disorders, a contraindication
to oral anticoagulation and pregnancy. All participating patients provided their signed
informed consent prior to the procedure.
Further prerequisites for inclusion in this study were as follows:
1. Pre-ablation treatment with a vitamin K antagonist (VKA) for a minimum of 3 weeks
and a therapeutic (above 2.0) international normalized ratio (INR) conﬁrmed on the
day of the procedure, and activated clotting time (ACT) levels above 300 s during
ablations.
2. Bi- or unilateral TCD recordings of sufﬁcient quality of the middle cerebral artery
(MCA) throughout the LA access period.
3. Ablation performed with one of 3 single-shot technologies designed for PVI: phased RF,
CB or nMARQ. As PVI with phased RF and the PVAC was performed with the use of 3
different versions of the GENius generator, and this was also accompanied by signiﬁcant
procedural modiﬁcations, the MES data acquired with this technology were analyzed
separately in 3 treatment groups (PVAC Groups I, II and III).
2.2. Pre-ablation evaluation and LA catheterization
Patients were admitted to the hospital 1 or 2 days prior to the procedure. Transesopha-
geal echocardiography was performed to exclude the presence of an intracardiac thrombus
within 24 h before the ablation. All patients received oral anticoagulation before the PVI,
with a target INR of 2.0 to 3.0.
All procedures were performed under conscious sedation with midazolam and
fentanyl. Decapolar (BARD Electrophysiology Inc., Lowell, MA, USA) and quadripolar
(Woxx 4 J, 6 F, Biotronik, SE & Co. KG, Berlin, Germany) catheters were advanced from
the femoral vein and positioned into the coronary sinus and the right ventricle. Sur-
face electrocardiograms and bipolar intracardiac electrograms were registered with
a Prucka, GE Medical digital recording system. A single transseptal puncture was per-
formed under ﬂuoroscopic, or in some cases under intracardiac echocardiographic (ICE)
guidance, using a Brockenbrough needle (St. Jude, Inc., Zaventem, Belgium) and a Swartz
sheath (St. Jude, Zaventem, Belgium). This sheath was exchanged for the deﬂectable 12 Fr
FlexCath sheath (Medtronic CryoCath LP, Kirkland, Quebec, Canada),whichwasﬂushed con-
tinuouslywith heparinized saline, andwhichwas usedwith any of the ablation catheters uti-
lized in this study. Immediately after the transseptal puncture, a 150 IU/kg body weight
intravenous (iv) heparin boluswas administered, followed by a continuous infusion tomain-
tain aminimumACT target level of 300 s during ablations. Additional 2000–5000 IU iv bolus-
es of heparin were administered as needed to attain the minimum target ACT level.
2.3. Ablation techniques
2.3.1. Phased RF ablation
The technical speciﬁcations of the PVAC and the GENius RF generator (Medtronic Inc.,
Minneapolis, MN, USA) have been described in detail [17–20]. The catheter was advanced
through the FlexCath sheath over a 0.032-inch guidewire (BARD Electrophysiology Inc.,
Lowell, MA, USA), which was positioned selectively in each PV. The electrical conduction
properties of the PV were assessed on the basis of the signals recorded by the PVAC
electrodes after placement inside the ostium. Before the ﬁrst RF application at each PV,the positions of the electrodes relative to the PV ostium were always conﬁrmed by
means of contrast injection through the FlexCath sheath. Care was always taken to apply
the RF outside the PV in the antral region, targeting potentials of high amplitude on as
many electrodes as possible for each application. RF energy was applied for 60 s, usually
3–4 times per PV, until PVI was achieved. The target temperature was 60 °C, measured
separately for all bipoles. Any electrode pair that failed to reach at least 50 °C during RF
delivery was switched off to avoid ineffective ED due to improper contact at the
electrode–tissue interface. Common ostia were isolated by inserting the guidewire into
the different side branches and ablating subsequent segments of the targeted veins. The
PV conduction was reassessed after each RF application, the electrodes being advanced
inside the ostium. The endpoint of the procedure was the electrical isolation of all PVs,
as conﬁrmed by an entrance block.
TheGENius RF generator is capable of delivering RF in a duty-cycledmodewith differ-
ent bipolar/unipolar ratios to any or all of the electrodes on the PVAC. Three consecutive
versions of the GENius RF generator (Medtronic Inc., Minneapolis, MN, USA) were used
in the course of recent years, also coupled with some proceduralmodiﬁcations as follows:
1. PVACGroup I. Initial series of ablationswere performedwith the use of software version
14.3 for the GENius generator. Bipolar/unipolar RF application was started at a ratio of
4:1 for eachPV and changed to a bipolar/unipolar ratio of 2:1 for a deeper lesionwhena
sufﬁcient reduction in local electrogramamplitude could not be achievedaftermultiple
RF deliveries. No attempts were made to avoid the potential interaction between the
ﬁrst and the last electrode (E1–E10) in the PVAC.
2. PVAC Group II. Ablations were performed with software version 14.4 for the GENius
generator. Modiﬁcations in the procedural technique were implemented in this
group of patients as follows. Potential interaction between the most distal (E1) and
the most proximal (E10) electrodes was considered and simultaneous EDs on these
poleswere attemptedonly afterﬂuoroscopic assessment of the interelectrodedistance,
which was considered adequate if the space between E1 and E10 was at least double
the ﬁxed 3-mm interelectrode distance as assessed frommultiple projections. Further-
more, ablationswere started in the 2:1mode and changed to 1:1 in those rare instances
when adequate amplitude change and PVI could not be achieved after multiple RF ap-
plications. In addition, the distal circular segment of the PVAC catheter was submerged
and captured by the introduction device in a saline bath prior to insertion into the
FlexCath sheath. This maneuver was used to prevent air entrapment around the
array and the introduction of air into the LA through the transseptal sheath.
3. PVAC Group III. Ablations were performed using the most recent software version
(15.1) for the GENius generator. RF delivery to E10 is not supported by this software
thereby excluding the possibility of E1–E10 interaction. No procedural modiﬁcations
as compared to those in PVAC Group II were implemented during these ablations.
2.3.2. CB ablation
The technology of CB ablation has been described in detail [17]. In brief, a 28-mm CB
was used in all cases. The CB was introduced into the PV ostium over an inner lumen
mapping catheter (Achieve, Medtronic Ablation Frontiers LCC, Carlsbad, CA, USA) which
is capable of mapping PV potentials before, during and after cryo applications. The best
possible occlusion of the PVs was facilitated by the steerable sheath and by positioning
the guidewire in a PV branch to provide maximal support. Furthermore, all special
maneuvers described previously, such as the “pull-down” or the “hockey stick”
techniques, were used as needed [21].
PV occlusion was assessed by means of a hand-held injection of contrast medium
(Optiray Covidien Deutschland GmbH, Neustadt/Donau, Germany) through the injection
side-port of the Arctic Front catheter. A minimum of two 5-min freezing cycles were
applied per PV. The balloon was repositioned for each application, preferably with the
guidewire situated in a different branch of the PV in order tomaximize the effect of freez-
ing at different aspects of the ostium. Before the start of ablation of the septal veins, a
quadripolar catheter was placed in the superior caval vein, where constant capture of
the right phrenic nerve could be achieved. One stimulus at maximal output was delivered
every 5 s, with manual assessment of the diaphragmatic movement. The freezing cycle
was terminated immediately if loss or weakening of the diaphragm response occurred.
PVI was assessed on the basis of the signals recorded by the Achieve wire.
2.3.3. nMARQ ablation
The nMARQ™ (Biosense Webster, Inc., Diamond Bar, CA, USA) is a multi-electrode,
irrigated RF ablation catheter with a uni-directional deﬂectable tip. The distal tip section
is circular or semilunar and contains 10 platinum ring electrodes with irrigation holes at
both ends for stimulation, recording and ablation. The diameter of the circular or semilu-
nar loop is variable to accommodate the LA anatomy. The catheter is integrated with the
CARTO 3 electroanatomical mapping system, which provides mapping and real-time
navigation capabilities. For ablation, the catheter is used in conjunction with the nMARQ
™ Multi-Channel RF Generator, which is able to deliver RF simultaneously to multiple
electrodes in unipolar or bipolar mode.
The circular-tip catheter was used exclusively in this study. The catheter was
advanced to the LA through the FlexCath guiding sheath. The 3-dimensional map of the
LA was constructed by using the CARTO™ electroanatomical mapping system (Biosense
Webster, Inc., Diamond Bar, CA, USA) equipped with Cartomerge™ software (Biosense
Webster, Inc., Diamond Bar, CA, USA). The pre-ablation cardiac CT image of the LA with
the proximal portions of the PVs was imported and registered for real-time mapping, fo-
cusing on the PVs and the PV antra of the LA. In addition, the positions of the electrodes
relative to the PV ostium were always conﬁrmed before the ﬁrst RF application at each
PV, by means of contrast injection through the FlexCath sheath. Care was taken to apply
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many electrodes as possible for each application. RF energy was applied for up to a
maximum of 60 s at a maximum of 20 W/electrode in the unipolar mode, with the target
temperature set at 43 °C. Electrodes not demonstrating the desired rise in temperature up
to 40 °C during energy delivery were switched off. The irrigation ﬂow rate between RF
applications was 4 ml/min, which was increased to 60 ml/min, starting 5 s before the
onset of RF application and maintained until 5 s after termination. The electrical
conduction properties of the PVs were assessed via the recordings through the electrodes
of the nMARQ catheter. The endpoint of the procedure was the electrical isolation of all
PVs, as conﬁrmed by an entrance block.
2.4. TCD recording and evaluation of the MES count
TCD recording was performed throughout the whole period of LA access (from the
transseptal puncture to the removal of all catheters and sheaths from the LA). The trans-
ducer was held in place by a proprietary headpiece supplied with the system. The MCAs
were bilaterally insonated from transtemporal windows by using a multifrequency
Doppler (Multi Dop T digital, DWL, QL software 2.8) which insonates simultaneously
with frequencies of 2 and 2.5 MHz. The system is capable of the automatic online identiﬁ-
cation of true MESs with a sensitivity of 100% and a speciﬁcity of 99.3% [22], and also of
discrimination between gaseous and solid emboli with a speciﬁcity of 96.5% [23]. The
identiﬁcation of true MESs with parallel artifact rejection is possible by implementing an
event detector system, using a previously published algorithm to detect high-intensity
signals due to emboli [22]. This step is followed by a second algorithm using data from
the dual-frequency insonation to determine whether the MESs are to be attributed to a
solid or to a gaseous embolus. Differentiation is possible because the reﬂection of ultra-
sound power is dependent not only on the size of the embolus, but also on its composition
and the insonating frequency used: solid emboli reﬂect more ultrasound at 2 MHz than at
2.5 MHz, whereas the opposite is true for gaseous emboli. TCD parameter settings as
recommended by the consensus criteria [24] were kept constant during the procedures.
The insonation depth was 45–55 mm, the sample volume was 8 mm, and the power
was 60–100mW. An example of a TCD record is given in Fig. 1. MES counts were collected
and evaluated separately during different stages of the procedure, as follows:
1. Transseptal puncture: the 30-s period after crossing the interatrial septum with the
transseptal needle.
2. PV angiography: contrast injection through the injection port of the CryoCath catheter
or the transseptal sheath during PVAC or nMARQ ablation.
3. Energy delivery: from the start until 15 s after the termination of ED.
4. The remainder of the procedure: that part of the LA access period duringwhich none of
the aforementioned maneuvers were performed.
As bilateral insonation of the MCA could not be achieved in all patients for technical
reasons, the results were provided as MES count per MCA, i.e. either the mean of bilateral
recordings or the number from the unilateral recording.
2.5. Statistical analyses
Statistical analysis was performed by using IBM SPSS 20. Data are reported as means
and standard deviation (SD). In the case of Fig. 1, data are shown as mean and 95%
conﬁdence intervals (95% CI). The normality of continuous variables was evaluated by
means of the Kolmogorov–Smirnov test. Statistical differences between groups were
determined by using analysis of variance when the data showed normal distribution
and homoscedasticity (Levene's statistic); otherwise, the Kruskal–Wallis test was
performed. For comparison of the MES counts obtained during CB ablation versus those
during the other 4 techniques, the Mann–Whitney test was used. In all statistical tests a
p value below 0.05 was considered as signiﬁcant.Fig. 1.Bilateralmultifrequency transcranial Dopplermonitoring of themiddle cerebral arteries. (
yellow line indicates the location of monitoring at 55mm insonation depth (MCA). (b)MCAwa
ing to cerebral microemboli during PV angiography. MCA, middle cerebral artery; ACA, anterio3. Results
3.1. Patient characteristics
A total of 89 patients were enrolled in the study. Demographic and
clinical parameters on the patients in the 5 treatment groups are
presented in Table 1. There were no signiﬁcant intergroup differences
in the baseline characteristics.
3.2. Procedural data
Procedural data are listed in Table 2. The total procedure,ﬂuoroscopy,
ED and LA access times demonstrated signiﬁcant differences. The acute
success rates were 100% in the 3 PVAC Groups, and 98% in both the CB
and the nMARQ groups. The shortest LA access time was achieved in
PVAC Group III, while the shortest ED timewas obtained during ablation
with the nMARQ. There were no signiﬁcant differences between the
intraprocedural ACT values. Symptomatic thromboembolic event did
not occur in any patient.
3.2.1. MES counts
The MES count detected with the CB was used as a reference
for comparisonwith the other technologies (Fig. 2, left panel). No signif-
icant difference was found between the CB group, PVAC Group II (p =
0.543) and PVAC Group III (p= 0.317) in the total cerebral MES counts.
However signiﬁcantly higher MES counts were demonstrated in PVAC
Group I (p = 0.005) and with the nMARQ technique (p = 0.007). The
ratios of gaseous versus solid MESs detected in the 5 treatment groups
did not differ signiﬁcantly (p = 0.688) (Fig. 2, right panel).
The distribution of the MES counts during different stages of the
procedure is depicted in Fig. 3. A relatively even distribution of embolus
formation was observed across the whole LA access time in the CB
group, and in PVACGroups II and III, whereas,microemboliwere detect-
ed mostly during ED in PVAC Group III and with nMARQ.
4. Discussion
Major differences have been reported in the incidence of SCI after AF
ablation with various technologies and with the different methods and
criteria applied to evaluate cerebral lesions. The diversity of the
periprocedural anticoagulation routine in the various studies further
hampers a direct comparison of the different AF ablation techniques.
In the present study, we compared different single-shot ablation tools
designed for PVIwithout additional LA ablation (e.g. creating long linear
lesions, or ablating complex fractionated electrograms) in patients with
similar baseline characteristics. Further, periprocedural anticoagulation
was homogeneous across all treatment groups with uninterrupted VKAa)Demonstration of beamalignment of both right and left sidedMCA andACA. Continuous
veform. Arrows on the right panel indicate the high intensity transient signals correspond-
r cerebral artery.
Table 1
Patient clinical characteristics.
Variable CB n = 13 PVAC I. n = 7 PVAC II. n = 37 PVAC III. n = 18 nMARQ n = 14 p
Age, years (SD) 57 (15) 54 (8) 60 (10) 55 (12) 53 (12) 0.372
Male, n (%) 9 (69) 6 (85) 25 (67.5) 12 (67) 10 (71)
Type of AF
Paroxysmal AF, n (%) 11 (84) 6 (85) 25 (67.5) 12 (67) 10 (71)
Persistent AF, n (%) 2 (16) 1 (15) 12 (32.5) 6 (33) 4 (29)
Arterial hypertension, n (%) 7 (53) 2 (28) 28 (75) 13 (72) 8 (57)
Diabetes mellitus, n (%) 0 (0) 2 (28) 3 (8) 1 (5.5) 1 (7)
LA short diameter, mm (SD) 41 (4) 40 (4) 42 (3.5) 43 (6) 42 (3.7) 0.825
LVEF, % (SD) 55 (4) 52 (8) 55 (5) 54 (10) 58 (5) 0.325
Mean CHADS2 score 0.62 0.71 0.92 0.83 0.64 0.491
Mean CHA2DS2-VASc score 1.23 0.86 1.65 1.39 1.14 0.309
AF, atrial ﬁbrillation; EF, ejection fraction; LA, left atrial; LV, left ventricular; CB, cryoballoon; PVAC, pulmonary vein ablation catheter.
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heparinization to a target ACT above 300 s in agreement with current
recommendations [25]. Any differences demonstrated in the number
of microemboli are therefore truly inherent to the ablation techniques
compared.
The rate of microembolization during phased RF ablation with the
implementation of speciﬁc procedural modiﬁcations and the use of
consecutive software versions of the GENius generator demonstrated
a signiﬁcant decrease in our study. The very same trend was observed
in recent DW MRI studies on the rate of new SCI lesions after phased
RF ablation. Importantly, no difference was detected in the level of
microembolization between the procedure with CB ablation versus
that with the PVAC after procedural and software changes had been im-
plemented (PVACGroups II and III). In contrast, signiﬁcantly higherMES
counts were recorded during phased RF ablation with the use of the old
technique (PVAC Group I) and during ablation with nMARQ (Fig. 2).
The signiﬁcant reduction in microembolization with phased RF was
clearly related to the elimination of the MESs during the ED period of
the procedure. Similarly to as observed in PVAC Group I, the majority
of the microemboli were generated during ED with nMARQ, which
also represents a multielectrode RF ablation technology (Fig. 3). It is
noteworthy that MESs were largely gaseous in nature in all treatment
groups.
4.1. Measures related to the reduction in cerebral embolization with phased
RF ablation
The signiﬁcant reduction achieved in clinically silent micro-
embolization, as demonstrated by DWMRI studies and our own results,
was related to reﬁnements in speciﬁc technical elements of the phased
RF ablation, based on preclinical data [12,13]. The observation of
enhanced microembolization with blended unipolar:bipolar energy
delivered through PVAC electrodes in close proximity to each other
was of utmost importance. While this problem remained unknown,
this was a likely common scenario, owing to the squeezed situation of
the distal PVAC loop. It should be noted that actual physical contact
between any two electrodes results in an electrical short circuit and im-
mediate termination of the RF delivery. On the other hand, no contact,
but a reduced interelectrode space (less than the ﬁxed 3 mm between
two neighboring electrodes mounted on the distal circular segment ofTable 2
Procedural parameters.
Procedural parameters CB n = 13 PVAC I n = 7
Total procedure time (min) (SD) 126 (24) 89 (23)
Fluoroscopy time (min) (SD) 28.8 (8) 17.7 (8.4)
Energy delivery time (min) (SD) 34.2 (18.8) 16 (4.5)
Left atrial access time (min) (SD) 80.8 (26) 70.4 (22.7)
Intraprocedural ACT (s) 340 380
Acute success rate (% of isolated PVs) 98 100
PV, pulmonary vein; other abbreviations as above.the PVAC) may lead to blood and tissue overheating, due to a high cur-
rent density. Simple measures to avoid this possibility include a careful
ﬂuoroscopic assessment of the electrode positions (as we did in PVAC
Group II), exclusion of simultaneous RF ED to electrodes 1 and 10, as
proposed by several authors [9–12] and a software modiﬁcation imple-
mented in the latest version of theGENius generator,which supports si-
multaneous RF delivery to amaximumof 9 electrodes (software version
15.1; PVAC Group III in our study).
The earlier practice of starting ED in a 4:1 bipolar:unipolar mode at
each PV was changed to start with a 2:1 ratio in PVAC Groups II and
III. The rationale for this change was to avoid extensive bipolar ED and
thereby reduce local heating between adjacent electrodes. Although
animal data suggested a tendency for more microemboli with more
bipolar RF delivery, the contribution of this change in the reduction of
microemboli is uncertain. Nonetheless, starting with the 2:1 instead of
the 4:1 ratio is the current practice at other centers [9–11,26].
As demonstrated in an animal model, a potential source of gaseous
emboli was the introduction of air into the LA via the transseptal sheath.
A signiﬁcantly larger air volume was measured during the introduction
of the PVAC, possibly owing to its more complex shape as compared
with a conventional focal RF catheter. To prevent air entrapment around
the array, the PVAC was submerged and captured by the introduction
device in a saline bath prior to insertion into the FlexCath sheath.
It is noteworthy that, in addition to the procedural changes as de-
scribed above, the GENius RF generator has also beenmodiﬁed in recent
years. An improved energy titration algorithm was implemented
starting at version 14.4 (PVAC Group II), which regulates the power de-
livery to control the maximum, instead of the average temperature,
with a target of 60 °C. Further, this software ensures a gradual and lim-
ited increase (4 W/s) during variable or intermittent electrode–tissue
contact, to avoid high temperature peaks. The importance of the cathe-
ter–tissue contact has been highlighted since the introduction of contact
force measurement for focal RF ablation catheters [27,28]. With multi-
polar ablation, this becomes even more critical, as the maintenance of
good contact simultaneously on multiple electrodes can be challenging
and the capability of direct contact force measurement with this tech-
nology is not yet available. This concept is supported by our previous
study: with an analysis of temperature and power data obtained
at high resolution sampling from the GENius generator, increased
microembolus formation was demonstrated during intermittentPVAC II n = 37 PVAC III n = 18 nMARQ n = 14 p
88 (16) 86 (25) 108 (25) b0.001
21.2 (8.8) 16.5 (5.3) 21.1 (7.8) 0.002
14.9 (4.1) 12 (2.8) 7.7 (3.4) b0.001
55.4 (15.1) 47.2 (13.6) 75.9 (27.4) b0.001
358 328 317 0.148
100 100 98
Fig. 2. Left panel: Total microembolic signal count in the ﬁve treatment groups. A plot of the mean number of microembolic signals (MESs) per middle cerebral artery in each treatment
group, as compared with the CB group. Right panel: Ratio of gaseous/solid emboli in the ﬁve treatment groups. (Abbreviations as in tables.)
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increased power which resulted in a temperature overshoot when the
contact was re-established [29]. The latest issue of the GENius software
(15.1; PVAC Group III) features the energy titration algorithmof version
14.4, and in addition, RF delivery is limited to 9 electrodes, thereby
providing a deﬁnite solution for the problem of E1–E10 interaction.
4.2. Microembolization during CB and nMARQ
Theuse of cryoenergy is generally regarded as amore “tissue-friendly”
and safer ablation technology, which is associated with a signiﬁcantly
lower incidence of thrombus formation as compared with RF ablation
[30]. The limited data available on microembolus generation with CB
ablation demonstrated consistent results. The total MES count during CB
ablation in the present study (1057 SD: 784) was reasonably similar
(834 SD: 727) to that recorded in our previous work [17], and to that
reported by Sauren et al. (935 SD: 463) [31]. Importantly, we also demon-
strated that the microemboli were predominantly gaseous, with an even
distribution throughout the LA access period. It should be noted that re-
sults obtained on SCI with different AF ablation technologies as evaluated
with DWMRI are in agreement with these TCD data [3].
Although the results obtained with the nMARQ ablation system
reﬂect our initial experience, we found this technology to be very effec-
tive with the shortest ED time required for acutely successful PVI in thisFig. 3.Microembolic signal counts during different stages of the procedure. (Abbreviations
as above).study. However, this technology was also associated with a high rate of
microembolization, of the magnitude of that initially achieved with
phased RF (PVAC Group I), and signiﬁcantly higher than the numbers
obtained with modiﬁed phased RF (PVAC Groups II and III) and with
CB. Recently published results of a German center [32] seem to support
our ﬁndings: DW MRI demonstrated SCI acutely in 14 (33%) out of 43
patients after PVI with the nMARQ catheter, a ratio similar to the values
up to 39% [2,6] in earlier reports on phased RF ablation.
The high microembolization rate was somewhat unexpected after
the earlier experience demonstrating lower incidence of SCI [3] and
lower microembolus counts [31] with focal irrigated as compared
with conventional RF ablation. As a potential explanation, one specula-
tive possibility is the irrigation itself used with the nMARQ catheter,
with a very high rate of 60 ml/min during ED. Direct injection of saline
into the LA at this rate is known to result in marked bubble formation
due to cavitation [33], which is readily visible on ICE (as we observed
in cases when ICE was used during ablations). This mechanism
could be responsible for a currently unknown proportion of cerebral
microemboli. These microemboli are gaseous, which are generally
considered to be less harmful than solid particles, although their signif-
icance in the long-term cognitive function is yet to bedetermined. Other
possible causes are likely to be inherent to multielectrode ablation and
the high total energy delivered when this catheter is used. By analyzing
biophysical parameters during phased RF ablation [28], our group earli-
er demonstrated that microemboli generation was related to both the
number of active electrodes during ED and the total energy delivered.
Further, maintenance of a good contact on multiple poles throughout
the entire duration of RF applications might be challenging, and power
handling in intermittent contact scenarios could therefore be of signiﬁ-
cance. There is an urgent need for more data on embolization rates and
in-depth investigations into the mechanism with the nMARQ system
with the aim of making this otherwise promising technology safer.
5. Limitations
This was a single-center investigation on a limited number of
patients. The study was non-randomized and the data were analyzed
retrospectively. However, this methodology did ensure that the patient
characteristics and periprocedural anticoagulation were homogeneous,
and differences in microembolization therefore represented true differ-
ences inherent to the ablation techniques compared.
6. Conclusions
A signiﬁcant decrease in the number of microemboli was demon-
strated when phased RF ablationwas implementedwith speciﬁc proce-
dural modiﬁcations with the use of newer generations of the GENius RF
generator. Microembolus counts were reduced to a level comparable
281A. Kiss et al. / International Journal of Cardiology 174 (2014) 276–281with that observed during CB ablation. A signiﬁcantly higher
microembolization rate, similar to that recorded with the ﬁrst version
of the GENius generator, was demonstrated with the multipolar irrigat-
ed nMARQ RF ablation system.
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